Journals / İstanbul Medical Journal / 2019 / Cilt: 20 - Sayı: 5

Delayed Surgical Resection After Long-course Neoadjuvant Chemoradiotherapy in Rectal Cancer: Single Center Experience

Rektum Kanserinde Uzun Süreli Neoadjuvan Kemoradyoterapi Sonrası Gecikmiş Cerrahi Rezeksiyon: Tek Merkez Deneyimi

Pages
424–430
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Introduction: The aim of this study was to evaluate whether delayed rectal cancer surgery after long-course neoadjuvant concomitant chemoradiotherapy was effective on pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The aim of this study was to evaluate whether delayed rectal cancer surgery after long-course neoadjuvant concomitant chemoradiotherapy was effective on pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS).
📊
Key Findings & Data:Methods: A total of 112 patients with rectal carcinoma diagnosed at the Radiation Oncology Clinic between 2011 and 2017 were retrospectively analyzed.
💡
Conclusion & Impact:We compared the outcomes of patients who were operated on greater than >9 weeks (delayed surgery) and less than
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: The aim of this study was to evaluate whether delayed rectal cancer surgery after long-course neoadjuvant concomitant chemoradiotherapy was effective on pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). Methods: A total of 112 patients with rectal carcinoma diagnosed at the Radiation Oncology Clinic between 2011 and 2017 were retrospectively analyzed. We compared the outcomes of patients who were operated on greater than >9 weeks (delayed surgery) and less than

Özet

Amaç: Bu çalışmanın amacı uzun süreli neoadjuvan kemoradyoterapiden sonra gecikmiş rektal kanser cerrahisinin patolojik tam yanıt (pCR), hastalıksız sağkalım (DFS), genel sağkalım (OS) için etkili olup olmadığını değerlendirmektir. Yöntemler: Retrospektif olarak, 2011-2017 yılları arasında Radyasyon Onkolojisi Kliniğine rektum karsinomu tanısı alan toplam 112 hastadan veri alındı. Neoadjuvan kemoradyoterapinin tamamlanmasından sonra >9 (9-12 hafta) haftadan uzun sürede ameliyat edilen ve 9 hafta ve 9 hafta sonra %5,2 vs %18,2 (p=0,032) daha yüksekti. Ameliyat sonrası >9 hafta içinde tümör regresyonu istatistiksel olarak anlamlılığa çok yakın bulundu (p=0,050). Ameliyat sonrası >9 hafta içinde postoperatif T evresinde azalma istatistiksel olarak anlamlı bulundu (p=0,007). Çalışma tamamlandığında, gecikmiş cerrahi uygulanan hasta grubu daha uzun ömürlü ve bu istatistiksel olarak anlamlı (p=0,044) idi. Gecikmiş cerrahi gurubunda genel OS (p=0,004) ve hastalıksız DFS (p=0,003) istatistiksel olarak anlamlı bulundu. Sonuç: Neoadjuvan kemoradyoterapi sonrası gecikmiş cerrahi patolojik tam yanıt oranı, hastalıksız sağkalım ve genel sağkalımı artırır.

🔖

Cite This Article

BEKTAŞ, H., ARSLAN, E., DURSUN, N., İNANÇ, B., YARDIMCI, A. H., MERMUT, Ö. (2022). Delayed Surgical Resection After Long-course Neoadjuvant Chemoradiotherapy in Rectal Cancer: Single Center Experience. İstanbul Medical Journal, Cilt: 20 - Sayı: 5, 424–430. https://ajindex.com/articles/551940

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005; 241: 829-36
  2. Lim CS, Mehigan BJ, Hartley JE, Monson JRT. Neoadjuvant therapy in the treatment of high risk rectal carcinoma. Surg Oncol 1999; 8: 1-11
  3. Marks G, Mohiuddin M, Masoni L, Montori A. High-dose preoperative radiation therapy as the key to extending sphincter-preservation surgery for cancer of the distal rectum. Surg Oncol Clin North Am 1992; 1: 71-86
  4. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R- 90-01 randomized trial. J Clin Oncol 1999; 17: 2396-402
  5. Bujko K. Timing of surgery following preoperative therapy in rectal cancer: there is no need for a prospective randomized trial. Dis Colon Rectum 2012; 55: e31
  6. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47: 141-6
  7. Al Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ. Predictors of pathologic response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol 2016; 23: 1177-86
  8. Wheeler JM, Dodds E, Warren BF, Cunningham C, George BD, Jones AC, et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum 2004; 47: 2025-31
  9. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012; 30: 1770-6
  10. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47: 141-6
  11. Wang L, Li ZY, Li ZW, Li YH, Sun YS, Ji JF, et al. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer. Dis Colon Rectum 2015; 58: 186-92
  12. Han YD, Kim WR, Park SW, Cho MS, Hur H, Min BS, et al. Predictors of pathologic complete response in rectal cancer patients